Mifamurtide

Mifamurtide

Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]	EU EMA: by INN
Pregnancy category	not investigated
Routes of administration	intravenous liposomal infusion over one hour
ATC code	L03AX15 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	N/A
Elimination half-life	minutes (in plasma) 18 hrs (terminal)
Identifiers
IUPAC name 2-[(N-{(2R)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]-propanoyl}-L-alanyl-D-isoglutaminyl-L-alanyl)amino]ethyl (2R)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate
CAS Number	83461-56-7 Y 838853-48-8 (mifamurtide sodium · xH2O)
PubChem CID	23725093
UNII	EQD2NNX741
KEGG	D06619 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C59H109N6O19P
Molar mass	1237.499 g/mol
3D model (JSmol)	Interactive image
SMILES CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1C(O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC
NY (what is this?)  (verify)

WikiDoc Resources for Mifamurtide
Articles
Most recent articles on Mifamurtide Most cited articles on Mifamurtide Review articles on Mifamurtide Articles on Mifamurtide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Mifamurtide Images of Mifamurtide Photos of Mifamurtide Podcasts & MP3s on Mifamurtide Videos on Mifamurtide
Evidence Based Medicine
Cochrane Collaboration on Mifamurtide Bandolier on Mifamurtide TRIP on Mifamurtide
Clinical Trials
Ongoing Trials on Mifamurtide at Clinical Trials.gov Trial results on Mifamurtide Clinical Trials on Mifamurtide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Mifamurtide NICE Guidance on Mifamurtide NHS PRODIGY Guidance FDA on Mifamurtide CDC on Mifamurtide
Books
Books on Mifamurtide
News
Mifamurtide in the news Be alerted to news on Mifamurtide News trends on Mifamurtide
Commentary
Blogs on Mifamurtide
Definitions
Definitions of Mifamurtide
Patient Resources / Community
Patient resources on Mifamurtide Discussion groups on Mifamurtide Patient Handouts on Mifamurtide Directions to Hospitals Treating Mifamurtide Risk calculators and risk factors for Mifamurtide
Healthcare Provider Resources
Symptoms of Mifamurtide Causes & Risk Factors for Mifamurtide Diagnostic studies for Mifamurtide Treatment of Mifamurtide
Continuing Medical Education (CME)
CME Programs on Mifamurtide
International
Mifamurtide en Espanol Mifamurtide en Francais
Business
Mifamurtide in the Marketplace Patents on Mifamurtide
Experimental / Informatics
List of terms related to Mifamurtide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Mifamurtide (trade name Mepact, marketed by Takeda) is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which is lethal in about a third of cases. The drug was approved in Europe in March 2009.

History

The drug was invented by Ciba-Geigy (now Novartis) in the early 1980s and sold to Jenner Biotherapies in the 1990s. In 2003, IDM Pharma bought the rights and developed it further. IDM Pharma was acquired by Takeda along with mifamurtide in June 2009.

Mifamurtide had already been granted orphan drug status by the U.S. Food and Drug Administration (FDA) in 2001, and the European Medicines Agency (EMA) followed in 2004. It was approved in the 27 European Union member states plus Iceland, Liechtenstein, and Norway by a centralized marketing authorization in March 2009. The drug was denied approval by the FDA in 2007. Mifamurtide has been licensed by the EMA since March, 2009.

Indications

Mifamurtide is indicated for the treatment of high-grade, nonmetastasizing, resectable osteosarcoma following complete surgical removal in children, adolescents, and young adults, aged two to 30 years. Osteosarcoma is diagnosed in about 1,000 individuals in Europe and the USA per year, most under the age of 30. The drug is used in combination with postoperative, multiagent chemotherapy to kill remaining cancer cells and improve a patient's chance of overall survival.

In a phase-III clinical trial in about 800 newly diagnosed osteosarcoma patients, mifamurtide was combined with the chemotherapeutic agents doxorubicin and methotrexate, with or without cisplatin and ifosfamide. The mortality could be lowered by 30% versus chemotherapy plus placebo. Six years after the treatment, 78% of patients were still alive. This equals an absolute risk reduction of 8% .

Adverse effects

In a clinical study, mifamurtide was given to 332 subjects (half of whom were under age of 16) and most side effects were found to be mild to moderate in nature. Most patients experience fewer adverse events with subsequent administration. Common side effects include fever (about 90%), vomiting, fatigue and tachycardia (about 50%), infections, anaemia, anorexia, headache, diarrhoea and constipation (>10%).

Pharmacokinetics

After application of the liposomal infusion, the drug is cleared from the plasma within minutes and is concentrated in lung, liver, spleen, nasopharynx, and thyroid. The terminal half-life is 18 hours. In patients receiving a second treatment after 11–12 weeks, no accumulation effects were observed.

Pharmacodynamics

Mifamurtide is a fully synthetic derivative of muramyl dipeptide (MDP), the smallest naturally occurring immune stimulatory component of cell walls from Mycobacterium species. It has similar immunostimulatory effects as natural MDP with the advantage of a longer half-life in plasma.

NOD2 is a pattern recognition receptor which is found in several kinds of white blood cells, mainly monocytes and macrophages. It recognises muramyl dipeptide, a component of the cell wall of bacteria. Mifamurtide simulates a bacterial infection by binding to NOD2, activating white cells. This results in an increased production of TNF-α, interleukin 1, interleukin 6, interleukin 8, interleukin 12, and other cytokines, as well as ICAM-1. The activated white cells attack cancer cells, but not, at least in vitro, other cells.

Interactions

• Theoretical considerations suggest calcineurin inhibitors like ciclosporin and tacrolimus might interact with mifamurtide because of their effect on macrophages.
• High-dose NSAIDs block the mechanism of mifamurtide in vitro.

Consequently, the combination of mifamurtide with these types of drugs is contraindicated. However, mifamurtide can be coadministered with low doses of NSAIDs. No evidence suggests mifamurtide interacts with the studied chemotherapeutics, or with the cytochrome P450 system.

Chemistry

Scheme of a liposome formed by phospholipids in an aqueous solution

Mifamurtide is muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic analogue of muramyl dipeptide. The side chains of the molecule give it a longer elimination half-life than the natural substance. The substance is applied encapsulated into liposomes (L-MTP-PE). Being a phospholipid, it accumulates in the lipid bilayer of the liposomes in the infusion.

Synthesis

One method of synthesis (shown first) is based on N,N'-dicyclohexylcarbodiimide (DCC) assisted esterification of N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine with N-hydroxysuccinimide, followed by a condensation with 2-aminoethyl-2,3-dipalmitoylglycerylphosphoric acid in triethylamine (Et₃N). A different approach (shown second) uses N-acetylmuramyl-L-alanyl-D-isoglutamine, hydroxysuccinimide and alanyl-2-aminoethyl-2,3-dipalmitoylglycerylphosphoric acid; that is, the alanine is introduced in the second step instead of the first.